Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows from Operating Activities
Net loss	$ (16,806,157)	$ (24,487,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,526,073	5,371,248
Noncash lease expense	79,526	270,778
Stock-based compensation	636,213	788,025
Loss on lease assignment and termination	5,733,298
Foreign exchange gain	(117,335)
Loss on disposal of long-lived assets	721,564	564,692
Loss on settlement of related party receivable	780,000
Loss on extinguishment of warrant liability	279,000
Loss on debt extinguishment	2,647,000	560,000
Change in fair value of warrant liability	(2,331,000)
Change in fair value of related party receivable	(230,000)	(140,000)
Change in fair value of non-convertible promissory notes, related party	(1,300,000)	20,000
Change in fair value of convertible promissory notes, related party	(7,791,321)	224,250
Change in fair value of contingent earn-out receivable, related party		(1,190,000)
Unrealized gain on short-term investments		(999)
(Increase) decrease in:
Accounts receivable	(36,418)	(828,588)
Prepaid expenses and other current assets	618,180	(379,592)
Inventory - raw materials	(4,795)	734,102
Other assets	203,135
Deposits	174,623	(26,622)
Accounts payable	1,650,217	(1,695,391)
Deferred revenue	152,837	(48,577)
Accrued expenses and other liabilities	720,952	110,767
Net Cash Used In Operating Activities	(9,694,408)	(20,717,748)
Cash Flows from Investing Activities
Purchase of short-term investments	(30,186)	(933,193)
Proceeds from sale of short-term investments	146,151	2,890,355
Purchases of property and equipment	(57,704)	(695,700)
Proceeds from disposal of property and equipment		564,692
Proceeds from sale of intellectual property license		1,000,000
Net Cash Provided by Investing Activities	58,261	2,826,154
Cash Flows from Financing Activities
Proceeds from settlement of related party receivable	550,000
Repayments of principal under finance lease	(692,236)	(714,669)
Proceeds from issuance of common stock	1,942,650	22,001,799
Stock issuance costs		(2,219,868)
Proceeds from issuance of convertible promissory note, related party		2,253,750
Proceeds from issuance of non-convertible promissory notes, related party	7,839,083	750,000
Proceeds from issuance of common stock through at-the-market		8,399
Proceeds from issuance of common stock upon exercise of warrants		178,424
Proceeds from issuance of common stock under ESPP		12,904
Repayments of non-convertible promissory notes, related party	(450,000)
Net Cash Provided by Financing Activities	9,189,497	22,270,739
Effect of exchange rate changes on cash and cash equivalents	261	(4,736)
Net (Decrease) Increase in Cash and Cash Equivalents	(446,389)	4,374,409
Cash and Cash Equivalents - Beginning of the Period	1,027,997	184,925
Cash and Cash Equivalents - End of the Period	581,608	4,559,334
Supplemental Disclosure for Cash Flow Information:
Right-of-use assets obtained upon finance lease modifications	65,245
Right-of-use assets surrendered upon operating lease modifications		(85,226)
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Exercise of August 2024 pre-funded warrants	257
Issuance of common stock from conversion of promissory note, related party	2,009,079
Vendor credit memo applied against capitalized lab equipment	$ 15,157
Reclassification of contingent earn-out receivable, related party to related party receivable		$ 1,430,000